RECORD OF TELEPHONE CONFERENCE
The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.
Vaccines, Blood & Biologics
Date: November 19, 2010
From: David C. Staten, Jr, MPH, CDR, USPHS
Subject: Follow-up discussion on GSK’s October meeting minutes and CR issues related to the free polysaccharide content
Summary: FDA clarified that the current data regarding the free polysaccharide content is not sufficient to address the CR comments. FDA requested additional data on the failed assays. FDA suggested that these data be submitted in advance of receiving the sponsor’s CR response. FDA suggested that the data be submitted to the sponsor’s IND and agreed to review the data in 60 days.